Press Releases

YEAR
Toggle Summary Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Feb. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the appointment of
View HTML
Toggle Summary Study Demonstrates Macrolide-Resistance in S. pneumoniae in the United States Exceeds 25 Percent Threshold Set in Current Community-Acquired Bacterial Pneumonia (CABP) Treatment Guidelines
Contemporary data demonstrate macrolide resistance in S. pneumoniae is 39.5 percent overall and greater than 25 percent in most regions of the country Macrolide resistance shown to be significantly more common in outpatients vs. inpatients, with rates as high as 45.3 percent vs.
View HTML
Toggle Summary Nabriva Therapeutics Announces Retirement of its Chief Financial Officer
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the retirement of Gary
View HTML
Toggle Summary Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences in January
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will
View HTML
Toggle Summary Nabriva Therapeutics Announces Pricing of $15 Million Public Offering
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the pricing of its
View HTML
Toggle Summary Nabriva Therapeutics Announces Proposed Public Offering
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has commenced a
View HTML
Toggle Summary Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China
- Amen ded agreement encompasses enhanced manufacturing collaboration and regulatory support -A ccelerates milestone payments to Nabriva , including fourth quarter 2020   payment of $1 million DUBLIN, Ireland , Dec. 07, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a
View HTML
Toggle Summary Nabriva Therapeutics Announces Date of 1-for-10 Reverse Stock Split
DUBLIN, Ireland , Dec. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-10 reverse stock
View HTML
Toggle Summary Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences
DUBLIN, Ireland , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two upcoming
View HTML
Toggle Summary Nabriva Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
-Relaunch of Xenleta ® and Sivextro ® commenced in late September-   - Type A Meeting with FDA for Contepo™ held on October 30 th - -Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical
View HTML

For Media Inquiries

E-mail: PR@nabriva.com


For Investor Relations

E-mail: IR@nabriva.com